213 related articles for article (PubMed ID: 29061642)
1. Multilayered Omics-Based Analysis of a Head and Neck Cancer Model of Cisplatin Resistance Reveals Intratumoral Heterogeneity and Treatment-Induced Clonal Selection.
Niehr F; Eder T; Pilz T; Konschak R; Treue D; Klauschen F; Bockmayr M; Türkmen S; Jöhrens K; Budach V; Tinhofer I
Clin Cancer Res; 2018 Jan; 24(1):158-168. PubMed ID: 29061642
[No Abstract] [Full Text] [Related]
2. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
3. Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.
Huang KK; Jang KW; Kim S; Kim HS; Kim SM; Kwon HJ; Kim HR; Yun HJ; Ahn MJ; Park KU; Ramnarayanan K; McPherson JR; Zhang S; Rhee JK; Vettore AL; Das K; Ishimoto T; Kim JH; Koh YW; Kim SH; Choi EC; Teh BT; Rozen SG; Kim TM; Tan P; Cho BC
Sci Rep; 2016 Jan; 6():19552. PubMed ID: 26790612
[TBL] [Abstract][Full Text] [Related]
4. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
[TBL] [Abstract][Full Text] [Related]
5. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma.
Ogawa T; Ogawa K; Shiga K; Furukawa T; Nagase H; Hashimoto S; Kobayashi T; Horii A
Eur Arch Otorhinolaryngol; 2010 Oct; 267(10):1599-606. PubMed ID: 20443017
[TBL] [Abstract][Full Text] [Related]
7. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
[TBL] [Abstract][Full Text] [Related]
8. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
9. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
10. [Up-regulation of human chorionic gonadotropin alpha subunit gene and human mitochondrial cytochrome c oxidase subunit II gene in cis-Diamminedichloroplatinum(II)-resistant human head and neck squamous carcinoma cells].
Higuchi E
Hokkaido Igaku Zasshi; 1999 May; 74(3):231-8. PubMed ID: 10422566
[TBL] [Abstract][Full Text] [Related]
11. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma.
Yamano Y; Uzawa K; Saito K; Nakashima D; Kasamatsu A; Koike H; Kouzu Y; Shinozuka K; Nakatani K; Negoro K; Fujita S; Tanzawa H
Int J Cancer; 2010 Jan; 126(2):437-49. PubMed ID: 19569180
[TBL] [Abstract][Full Text] [Related]
12. Differentially expressed genes associated with CIS-diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and CDNA microarray.
Higuchi E; Oridate N; Furuta Y; Suzuki S; Hatakeyama H; Sawa H; Sunayashiki-Kusuzaki K; Yamazaki K; Inuyama Y; Fukuda S
Head Neck; 2003 Mar; 25(3):187-93. PubMed ID: 12599285
[TBL] [Abstract][Full Text] [Related]
13. Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Melchardt T; Magnes T; Hufnagl C; Thorner AR; Ducar M; Neureiter D; Tränkenschuh W; Klieser E; Gaggl A; Rösch S; Rasp G; Hartmann TN; Pleyer L; Rinnerthaler G; Weiss L; Greil R; Egle A
Eur J Cancer; 2018 Apr; 93():69-78. PubMed ID: 29477794
[TBL] [Abstract][Full Text] [Related]
14. Is there a role for the Fas-/Fas-Ligand pathway in chemoresistance of human squamous cell carcinomas of the head and neck (SCCHN)?
Sproll KC; Balló H; Hoffmann TK; Scheckenbach K; Koldovsky U; Balz V; Hafner D; Ramp U; Bier H
Oral Oncol; 2009 Jan; 45(1):69-84. PubMed ID: 18620901
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
16. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
17. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 enhances cisplatin resistance of human tongue squamous cell carcinoma.
Zhuang XM; Zhou B
J Oral Pathol Med; 2019 Feb; 48(2):122-128. PubMed ID: 30554431
[TBL] [Abstract][Full Text] [Related]
19. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
20. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
